Chengdu Suncadia Medicine Co., Ltd.
Clinical trials sponsored by Chengdu Suncadia Medicine Co., Ltd., explained in plain language.
-
New drug aims to protect kidneys in IgA nephropathy patients
Disease control Recruiting nowThis study tests the long-term safety of HRS-5965 capsules in 380 adults with primary IgA nephropathy, a kidney disease. Participants will take the drug and be monitored for side effects, as well as changes in urine protein and kidney function. The goal is to see if HRS-5965 can …
Phase: PHASE2 • Sponsor: Chengdu Suncadia Medicine Co., Ltd. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug HRS-1635 enters early human testing for hard-to-treat blood cancers
Disease control Recruiting nowThis early-phase study tests the safety and tolerability of a new drug called HRS-1635 in 180 adults with B-cell blood cancers that have come back or not responded to treatment. Researchers will find the best dose and watch for side effects. The goal is to control the disease, no…
Phase: PHASE1 • Sponsor: Chengdu Suncadia Medicine Co., Ltd. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New heart drug HRS-5765 takes first step in human safety trial
Knowledge-focused Recruiting nowThis early-stage study tests the safety of a new oral drug called HRS-5765, which may one day treat heart failure. About 74 healthy adults aged 18-65 will receive single or multiple doses to see how the drug moves through the body and if it causes side effects. No direct treatmen…
Phase: PHASE1 • Sponsor: Chengdu Suncadia Medicine Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC